Efficacy of High-precision Transcranial Direct Current Stimulation on Anxiety Disorders
1 other identifier
interventional
60
1 country
1
Brief Summary
- 1.Current research has found that tDCS has a positive effect on improving the negative attention bias of AD patients, and this study uses HD-tDCS intervention to improve the cognitive function and neural mechanisms of AD patients in the OFC to provide a theoretical basis for AD neural mechanism research. Verify Hypothesis 1: HD-tDCS cathodal stimulation of the left OFC reduces the excitability of this region, modulates its connectivity with the attentional function network, and thus changes the emotional experience of social threat.
- 2.Currently, there is no consensus on the stimulation parameters for tDCS in the treatment of AD, and more evidence is needed to prove and explore. It is hoped that the HD-tDCS intervention protocol will become an effective treatment method for improving cognitive function and clinical symptoms in AD patients. Hypothesis 2: The HD-tDCS with intensified stimulation parameters (2mA, twice a day, with a 20-minute interval, for 5 consecutive days) has an impact on the main and secondary clinical variables of AD patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 6, 2024
CompletedStudy Start
First participant enrolled
July 30, 2024
CompletedFirst Posted
Study publicly available on registry
July 31, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2025
CompletedJuly 31, 2024
July 1, 2024
1 year
July 6, 2024
July 26, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Hamilton Anxiety Scale
HAMA was assessed at baseline and late 5 days after treatment by a professionally trained physician (non-trial intervention) to understand the effectiveness of treatment. Clinical efficacy evaluation criteria: 75% was recovered, 50% was significant, 25% was effective, and \<25% was invalid.
1 week
Study Arms (2)
High-definition transcranial direct current stimulation
EXPERIMENTALHD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
High-definition transcranial direct current stimulation pseudo-stimulation control group
ACTIVE COMPARATORThe treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
Interventions
HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
Eligibility Criteria
You may qualify if:
- Meet the DSM-5 AD diagnostic criteria;
- The Chinese version of the Brief International Neuropsychiatric Interview (MINI) screening meets the diagnosis;
- Age: 18-55 years old;
- The patient participated voluntarily, obtained the consent of the family members, and signed the informed consent form;
- Scale score criteria: 14 points on the Hamilton Anxiety Scale (HAMA) and 17 points on the Hamilton Depression Scale (HAMD).
You may not qualify if:
- Neurological diseases or other psychiatric disorders;
- severe somatic diseases;
- received medical treatment including medication, psychotherapy, electroconvulsive therapy, and physical therapy within the first half months of enrollment;
- tDCS examination contraindications, such as intracranial metal or electronic implants, skull plate, or other skull implants.
- Pregnancy and lactation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanjing Brain Hospital
Nanjing, Jiangsu, 210024, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
July 6, 2024
First Posted
July 31, 2024
Study Start
July 30, 2024
Primary Completion
July 30, 2025
Study Completion
December 30, 2025
Last Updated
July 31, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share